| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 129.89% | Maxim Group | → $30 | Upgrades | Hold → Buy |
| 07/26/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/22/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 05/20/2021 | -31.03% | Baird | → $9 | Initiates Coverage On | → Outperform |
| 02/18/2021 | -54.02% | Jefferies | → $6 | Initiates Coverage On | → Buy |
| 01/04/2021 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 10/08/2020 | -54.02% | Aegis Capital | → $6 | Initiates Coverage On | → Buy |
| 08/28/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/22/2019 | -94.64% | Chardan Capital | $22 → $0.7 | Downgrades | Buy → Neutral |
What is the target price for Vistagen Therapeutics (VTGN)?
The latest price target for Vistagen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on August 7, 2023. The analyst firm set a price target for $30.00 expecting VTGN to rise to within 12 months (a possible 129.89% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vistagen Therapeutics (VTGN)?
The latest analyst rating for Vistagen Therapeutics (NASDAQ: VTGN) was provided by Maxim Group, and Vistagen Therapeutics upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Vistagen Therapeutics (VTGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vistagen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vistagen Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
Is the Analyst Rating Vistagen Therapeutics (VTGN) correct?
While ratings are subjective and will change, the latest Vistagen Therapeutics (VTGN) rating was a upgraded with a price target of $0.00 to $30.00. The current price Vistagen Therapeutics (VTGN) is trading at is $13.05, which is within the analyst's predicted range.